Silexion Therapeutics Corp (NASDAQ:SLXN) has a beta value of 0.24 and has seen 54.19 million shares traded in the recent trading session. The company, currently valued at $9.04M, closed the recent trade at $1.04 per share which meant it gained $0.34 on the day or 47.95% during that session. The SLXN stock price is -11632.69% off its 52-week high price of $122.02 and 45.19% above the 52-week low of $0.57. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.19 million shares traded. The 3-month trading volume is 13.43 million shares.
Silexion Therapeutics Corp (NASDAQ:SLXN) trade information
Sporting 47.95% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the SLXN stock price touched $1.04 or saw a rise of 19.38%. Year-to-date, Silexion Therapeutics Corp shares have moved -48.25%, while the 5-day performance has seen it change 31.66%. Over the past 30 days, the shares of Silexion Therapeutics Corp (NASDAQ:SLXN) have changed -7.13%. Short interest in the company has seen 0.38 million shares shorted with days to cover at 0.08.
Silexion Therapeutics Corp (SLXN) estimates and forecasts
The company’s shares have lost -68.68% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -286.10% over the past 5 years. Earnings growth for 2025 is a modest 96.36% while over the next 5 years, the company’s earnings are expected to increase by 59.98%.
SLXN Dividends
Silexion Therapeutics Corp is expected to release its next earnings report on 2025-Mar-17 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Silexion Therapeutics Corp (NASDAQ:SLXN)’s Major holders
Insiders own 5.98% of the company shares, while shares held by institutions stand at 7.18% with a share float percentage of 7.64%. Investors are also buoyed by the number of investors in a company, with Silexion Therapeutics Corp having a total of 6.0 institutions that hold shares in the company.
